全文获取类型
收费全文 | 105224篇 |
免费 | 6721篇 |
国内免费 | 440篇 |
专业分类
耳鼻咽喉 | 1136篇 |
儿科学 | 2857篇 |
妇产科学 | 1931篇 |
基础医学 | 13296篇 |
口腔科学 | 1842篇 |
临床医学 | 11115篇 |
内科学 | 21253篇 |
皮肤病学 | 1390篇 |
神经病学 | 10385篇 |
特种医学 | 4042篇 |
外国民族医学 | 3篇 |
外科学 | 16809篇 |
综合类 | 1213篇 |
一般理论 | 133篇 |
预防医学 | 8728篇 |
眼科学 | 2167篇 |
药学 | 6840篇 |
中国医学 | 120篇 |
肿瘤学 | 7125篇 |
出版年
2023年 | 578篇 |
2022年 | 955篇 |
2021年 | 2149篇 |
2020年 | 1369篇 |
2019年 | 2163篇 |
2018年 | 2650篇 |
2017年 | 1883篇 |
2016年 | 2035篇 |
2015年 | 2352篇 |
2014年 | 3535篇 |
2013年 | 4865篇 |
2012年 | 7774篇 |
2011年 | 8190篇 |
2010年 | 4688篇 |
2009年 | 4222篇 |
2008年 | 7315篇 |
2007年 | 7639篇 |
2006年 | 7362篇 |
2005年 | 7090篇 |
2004年 | 6918篇 |
2003年 | 6228篇 |
2002年 | 5885篇 |
2001年 | 1011篇 |
2000年 | 721篇 |
1999年 | 1046篇 |
1998年 | 1294篇 |
1997年 | 971篇 |
1996年 | 815篇 |
1995年 | 727篇 |
1994年 | 640篇 |
1993年 | 616篇 |
1992年 | 567篇 |
1991年 | 513篇 |
1990年 | 426篇 |
1989年 | 402篇 |
1988年 | 391篇 |
1987年 | 373篇 |
1986年 | 335篇 |
1985年 | 354篇 |
1984年 | 362篇 |
1983年 | 296篇 |
1982年 | 367篇 |
1981年 | 307篇 |
1980年 | 255篇 |
1979年 | 144篇 |
1978年 | 173篇 |
1977年 | 139篇 |
1976年 | 116篇 |
1974年 | 95篇 |
1973年 | 110篇 |
排序方式: 共有10000条查询结果,搜索用时 8 毫秒
21.
22.
23.
Najat C Daw Wayne L Furman Clinton F Stewart Lisa C Iacono Mark Krailo Mark L Bernstein Janet E Dancey Rose Anne Speights Susan M Blaney James M Croop Gregory H Reaman Peter C Adamson 《Journal of clinical oncology》2005,23(25):6172-6180
PURPOSE: Epidermal growth factor receptor is expressed in pediatric malignant solid tumors. We conducted a phase I trial of gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor, in children with refractory solid tumors. PATIENTS AND METHODS: Gefitinib (150, 300, 400, or 500 mg/m2) was administered orally to cohorts of three to six patients once daily continuously until disease progression or significant toxicity. Pharmacokinetic studies were performed during course one (day 1 through 28). RESULTS: Of the 25 enrolled patients, 19 (median age, 15 years) were fully evaluable for toxicity and received 54 courses. Dose-limiting toxicity was rash in two patients treated with 500 mg/m2 and elevated ALT and AST in one patient treated with 400 mg/m2. The maximum-tolerated dose was 400 mg/m2/d. The most frequent non-dose-limiting toxicities were grade 1 or 2 dry skin, anemia, diarrhea, nausea, and vomiting. One patient with Ewing's sarcoma had a partial response. Disease stabilized for 8 to > or = 60 weeks in two patients with Wilms' tumor and two with brainstem glioma (one exophytic). At 400 mg/m2, the median peak gefitinib plasma concentration was 2.2 microg/mL (range, 1.2 to 3.6 microg/mL) and occurred at a median of 2.3 hours (range, 2.0 to 8.3 hours) after drug administration. The median apparent clearance and median half-life were 14.8 L/h/m2 (range, 3.8 to 24.8 L/h/m2) and 11.7 hours (range, 5.6 to 22.8 hours), respectively. Gefitinib systemic exposures were comparable with those associated with antitumor activity in adults. CONCLUSION: Oral gefitinib is well tolerated in children. Development of the drug in combination with cytotoxic chemotherapy will be pursued. 相似文献
24.
Practical management of patients with non-small-cell lung cancer treated with gefitinib. 总被引:7,自引:0,他引:7
Neelam T Shah Mark G Kris William Pao Leslie B Tyson Barbara M Pizzo Murk-Hein Heinemann Leah Ben-Porat Dana L Sachs Robert T Heelan Vincent A Miller 《Journal of clinical oncology》2005,23(1):165-174
PURPOSE: The use of gefitinib, the first drug approved to inhibit the epidermal growth factor receptor tyrosine kinase, is indicated in patients with non-small-cell lung cancer with tumors progressive after chemotherapy. The unique mechanism of action of this agent leads to distinctive patterns of response and toxicity in persons with lung cancer. Many of the principles of management relevant to gefitinib are distinct from those with conventional cytotoxic drugs. To meet this need, we present practical guidelines on the use of gefitinib in patients with non-small-cell lung cancer. METHODS: This article reviews gefitinib's indications, dosing, response phenomena, and patterns of relapse in individuals with radiographic response. RESULTS: We present our recommendations for the management of rash and diarrhea caused by this agent. CONCLUSION: This information can guide practitioners and help them inform their patients about what to expect when they receive gefitinib. 相似文献
25.
26.
27.
28.
Anneloes Dirks Lucianne Groenink Koen G C Westphal Jocelien D A Olivier P Monika Verdouw Jan van der Gugten Mark A Geyer Berend Olivier 《Neuropsychopharmacology》2003,28(10):1790-1798
Chronically elevated levels of corticotropin-releasing factor (CRF) in transgenic mice overexpressing CRF in the brain (CRF-OE) appear to be associated with alterations commonly associated with major depressive disorder, as well as with sensorimotor gating deficits commonly associated with schizophrenia. In the present study, we tested the hypothesis that antipsychotics may be effective in normalizing prepulse inhibition (PPI) of acoustic startle in CRF-OE mice, which display impaired sensorimotor gating compared to wild-type (WT) mice. The typical antipsychotic haloperidol and atypical antipsychotic risperidone improved PPI in the CRF-OE mice, but were ineffective in WT mice. The atypical antipsychotic clozapine did not influence PPI in CRF-OE mice, but reduced gating in WT mice. This effect of clozapine in the CRF-OE mice may thus be regarded as a relative improvement, consistent with the observed effect of haloperidol and risperidone. As expected, the anxiolytic, nonantipsychotic chlordiazepoxide was devoid of any effect. All four compounds dose-dependently reduced the acoustic startle response irrespective of genotype. These results indicate that antipsychotic drugs are effective in improving startle gating deficits in the CRF-OE mice. Hence, the CRF-OE mouse model may represent an animal model for certain aspects of psychotic depression, and could be a valuable tool for research addressing the impact of chronically elevated levels of CRF on information processing. 相似文献
29.
Hillary R Bogner Mark S Cary Martha L Bruce Charles F Reynolds Benoit Mulsant Thomas Ten Have George S Alexopoulos 《The American journal of geriatric psychiatry》2005,13(10):861-868
OBJECTIVE: The authors described the influence of specific medical conditions on clinical remission and response of major depression (MDD) in a clinical trial evaluating a care-management intervention among older primary-care patients. METHODS: Adults age 60 years and older were randomly selected and screened for depression. Participants were randomly assigned to Usual Care or to an Intervention with a depression care-manager offering algorithm-based care for MDD. In all, 324 adults meeting criteria for MDD were included in these analyses. Remission and response was defined by a score on the Hamilton Rating Scale for Depression <10 and by a decrease from baseline of > or =50%, respectively. Medical comorbidity was ascertained through self-report. Cognitive impairment was defined by a score <24 on the Mini-Mental State Exam (MMSE). RESULTS: In Usual Care, rates of remission were faster in persons who reported atrial fibrillation (AF) than in persons who did not report AF and slower in persons who reported chronic pulmonary disease than in persons who did not report chronic pulmonary disease; rates of response were less stable in persons with MMSE <24 than in those with MMSE > or =24. In the Intervention condition, none of the specific chronic medical conditions were significantly associated with outcomes for MDD. CONCLUSIONS: Because disease-specific findings were observed in persons who received Usual Care but not in persons who received more intensive treatment in the Intervention condition, our results suggest that the association of medical comorbidity and treatment outcomes for MDD may be determined by the intensity of treatment for depression. 相似文献
30.